冠昊生物收盘下跌2.86%，滚动市盈率164.85倍，总市值45.98亿元

Core Insights - The company, Guanhao Biological, closed at 17.34 yuan on August 20, with a decline of 2.86%, resulting in a rolling PE ratio of 164.85 times and a total market value of 4.598 billion yuan [1] - The average PE ratio in the medical device industry is 59.32 times, with a median of 39.97 times, placing Guanhao Biological at the 110th position in the industry ranking [1] - As of August 8, 2025, the number of shareholders for Guanhao Biological increased to 33,463, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Guanhao Biological Co., Ltd. operates in three main business segments: biomaterials, pharmaceuticals, and cells, with key products including biological dura (spinal) membrane patches and sterile biological dressings [1] - The company is recognized as a "National Intellectual Property Advantage Enterprise," with its trademarks included in the key trademark protection list of Guangdong Province [1] - Guanhao Biological and its subsidiaries are classified as high-tech enterprises and specialized small and medium-sized enterprises in Guangdong Province [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 94.7971 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.8661 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - The company's PE ratios are significantly higher than the industry averages, with a TTM PE of 164.85 and a static PE of 167.70 [2] - Comparatively, other companies in the industry have lower PE ratios, with the highest being 20.96 for Antu Biological, indicating a potential overvaluation for Guanhao Biological [2]